

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **UNITED GENE HIGH-TECH GROUP LIMITED**

**聯合基因科技集團有限公司**

*(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)*

**(Stock Code: 399)**

### **PROFIT WARNING**

This announcement is made by the Company pursuant to Rule 13.09 of the Listing Rules and the Inside Information Provisions under Part XIVA of the SFO.

The Board wishes to inform the shareholders of the Company and potential investors that, based on a preliminary review of the unaudited consolidated management accounts of the Group for the six months ended 31 December 2013, the Group is expected to record a substantial increase in the consolidated net loss for the six months ended 31 December 2013 as compared with the corresponding period in 2012, due to a loss on the acquisition of the convertible bonds issued by Extrawell Pharmaceutical Holdings Limited (“**Extrawell**”), which represented the excess of the fair value of the convertible bonds of the Company issued as consideration over the fair value of the convertible bonds of Extrawell, pursuant to the very substantial acquisition and connected transaction as announced on 15 May 2013 and the impairment loss on the investment in associate, Extrawell.

The information contained in this announcement is only a preliminary assessment by the Board based on the information currently available and the unaudited consolidated management accounts of the Group for the six months ended 31 December 2013, which have not been reviewed, confirmed nor audited by the Company’s independent auditors.

**Shareholders of the Company and potential investors are advised to exercise caution when dealing in the securities of the Company.**

This announcement is made by United Gene High-Tech Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571, Law of Hong Kong) (the “**SFO**”).

Based on a preliminary review by the board of directors of the Company (the “**Board**”) of the unaudited consolidated management accounts of the Group for the six months ended 31 December 2013, the Board wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that the Group is expected to record a substantial increase in the consolidated net loss for the six months ended 31 December 2013 as compared with the corresponding period in 2012. Based on the preliminary review of the relevant information currently available to the Company, increase in the consolidated net loss was mainly attributable to a loss on the acquisition of the convertible bonds issued by Extrawell Pharmaceutical Holdings Limited (“**Extrawell**”), which represented the excess of the fair value of the convertible bonds of the Company issued as consideration over the fair value of the convertible bonds of Extrawell, pursuant to the very substantial acquisition and connected transaction as announced on 15 May 2013 and the impairment loss on the investment in associate, Extrawell.

As the Company is still in the process of preparing and finalizing its interim results for the six months ended 31 December 2013, the information contained in this announcement is only a preliminary assessment by the Board based on the information currently available and the unaudited consolidated management accounts of the Group for the six months ended 31 December 2013, which have not been reviewed, confirmed nor audited by the Company’s independent auditors. The actual interim results of the Group for the six months ended 31 December 2013 may be different from what is disclosed in this announcement.

The interim results of the Group for the six months ended 31 December 2013 are expected to be announced by the Company by 28 February 2014. Shareholders and potential investors are advised to read the interim results announcement of the Company carefully when it is published.

**Shareholders of the Company and potential investors are advised to exercise caution when dealing in the securities of the Company.**

By Order of the Board  
**United Gene High-Tech Group Limited**  
**Lee Nga Yan**  
*Executive Director*

Hong Kong, 20 February 2014

*As at the date of this announcement, the Board comprises Ms. Jiang Nian (chairman & non-executive Director), Ms. Lee Nga Yan (executive Director), Dr. Guo Yi (executive Director), Ms. Xiao Yan (non-executive Director), Ms. Wu Yanmin (non-executive Director), Ms. Chen Weijun (independent non-executive Director), Dr. Zhang Zhihong (independent non-executive Director) and Mr. Wang Rongliang (independent non-executive Director).*